This handout is for alcohol-related atrial flutter ("holiday heart syndrome"). Your care team identified this based on: new-onset palpitations, dyspnea, or fatigue within 12-48 h of acute alcohol binge (>5 drinks/day in 1 day) in patient without known structural heart disease — holiday heart syndrome screen.
Other reasons your team may use this plan: atrial flutter (or af) on 12-lead ecg with documented recent alcohol binge — confirm and trigger acute management; recurrent flutter episodes in patient with chronic heavy drinking (per audit-c ≥4 male / ≥3 female, or self-reported >14 drinks/week male / >7 drinks/week female) — chronic alcohol-related flutter pattern; syncope, hypotension, or chest pain with flutter on monitor in post-binge patient — emergent rate/rhythm management.
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| metoprolol_tartrate | 5 mg IV q5min × 3 then 25-50 mg PO BID | IV/PO | IV q5min × 3 → PO BID | AVN slowing for flutter; preferred over non-DHP CCB if alcoholic cardiomyopathy suspected (any LV dysfunction); ACC/AHA 2024 (PMID 38753446) Class I rate control |
| metoprolol_succinate | 25-50 mg PO daily | PO | daily | Once-daily formulation for outpatient transition; ACC/AHA 2024 |
| diltiazem | 0.25 mg/kg IV bolus then 5-15 mg/h infusion OR 30-60 mg PO QID | IV/PO | continuous IV / QID PO | Alternative AVN blocker; AVOID if EF <40 or alcoholic CMP — can worsen HF; ACC/AHA 2024 Class I |
| apixaban | 5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) | PO | BID | 4-wk post-CV AC mandatory per ACC/AHA 2024 (PMID 38753446); long-term AC if CHA2DS2-VASc ≥2; ARISTOTLE foundational (PMID 21870978); DOAC preferred over warfarin in non-valvular flutter |
| rivaroxaban | 20 mg with food (15 mg if CrCl 15-50) | PO | once daily | ROCKET-AF reference; alternative DOAC |
| dabigatran | 150 mg BID (110 mg BID if ≥80 yr or higher bleed risk; avoid CrCl <30) | PO | BID | RE-LY reference; idarucizumab available for emergent reversal — useful in alcohol-related patients with elevated falls/GIB risk |
| warfarin | 5 mg daily; INR target 2-3 | PO | daily | Cirrhosis Child-Pugh C contraindicates DOACs (apixaban can be used in Child-Pugh B with caution); warfarin alternative if DOAC contraindicated; INR monitoring challenging in heavy drinkers |
| magnesium_sulfate | 2-4 g IV over 15-30 min then 1-2 g IV q4-6h to Mg ≥2.0 | IV | q4-6h until repleted | Hypomagnesemia common in binge drinkers; Mg repletion supports rhythm stability + cardioversion success; ACC/AHA 2024 supportive measure |
| potassium_chloride | 40-80 mEq PO/IV over 4 h to K ≥4.0; max 10 mEq/h IV peripheral | PO/IV | until repleted | Hypokalemia common from binge + emesis; K repletion reduces ectopy + supports rhythm stability |
| lorazepam | 1-4 mg PO/IV q1h symptom-triggered per CIWA protocol | PO/IV | q1h CIWA-triggered | CIWA-Ar protocol for alcohol withdrawal management; severe withdrawal (CIWA >15) requires aggressive benzodiazepine treatment + ICU consideration; withdrawal can perpetuate flutter via sympathetic surge |
| naltrexone | 50 mg PO daily OR 380 mg IM monthly | PO/IM | daily/monthly | FDA-approved AUD pharmacotherapy; reduces alcohol craving + heavy drinking days; SBIRT-driven referral pathway; AUDIT-C ≥4/3 is positive screen |
| thiamine | 100 mg IV/IM × 3 doses then 100 mg PO daily | IV/IM/PO | TID acute → daily long-term | Wernicke prophylaxis — give BEFORE glucose to avoid precipitating WE; standard alcohol-admission protocol |
Plan: Alcohol-related atrial flutter ("Holiday Heart") — acute rate/rhythm + electrolyte repletion + alcohol cessation/SBIRT + lifestyle modification per LEGACY pathway — ACC/AHA 2024 (PMID 38753446) + ALCOHOL-AF (PMID 31893513)
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
AUDIT-C reassessment at 4 wk + 3 mo; alcohol abstinence (preferred per ALCOHOL-AF) or significant reduction goal; lifestyle bundle per LEGACY (sleep, weight, exercise); recurrence monitoring (Holter or smartwatch); EP referral if recurrent despite abstinence (consider CTI ablation if typical morphology); cardiology + addiction medicine + primary care coordination; long-term AC reassessment per CHA2DS2-VASc trajectory
Guideline: 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar PMID 38753446) + ESC 2024 AF (Van Gelder PMID 39050851) + ALCOHOL-AF (Voskoboinik NEJM 2020 PMID 31893513) + LEGACY (Pathak JACC 2014 PMID 25788534)